These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4384520)

  • 21. [Desensitization to salicylazosulfapyridine (Salazopyrin) in a patient with ulcerative colitis].
    Chiba M; Murata M; Ihzuka M; Ohta H; Arakawa H; Masamune O; Ohkubo M
    Nihon Shokakibyo Gakkai Zasshi; 1986 Jan; 83(1):113-6. PubMed ID: 2871206
    [No Abstract]   [Full Text] [Related]  

  • 22. Multiple haematologic abnormalities associated with sulfasalazine.
    Wheelan KR; Cooper B; Stone MJ
    Ann Intern Med; 1982 Nov; 97(5):726-7. PubMed ID: 6127975
    [No Abstract]   [Full Text] [Related]  

  • 23. Salicylazosulfapyridine and male infertility.
    Heineman MJ; Dony JM; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1981 Nov; 12(5):297-303. PubMed ID: 6120861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease.
    Nielsen OH
    Scand J Gastroenterol; 1982 Apr; 17(3):389-93. PubMed ID: 6127793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulfasalazine-induced DRESS and severe agranulocytosis successfully treated by granulocyte colony-stimulating factor.
    Fathallah N; Slim R; Rached S; Hachfi W; Letaief A; Ben Salem C
    Int J Clin Pharm; 2015 Aug; 37(4):563-5. PubMed ID: 25854308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythroderma and toxic epidermal necrolysis caused by to 5-aminosalacylic acid.
    Iemoli E; Piconi S; Ardizzone S; Bianchi Porro G; Raimond F
    Inflamm Bowel Dis; 2006 Oct; 12(10):1007-8. PubMed ID: 17012974
    [No Abstract]   [Full Text] [Related]  

  • 27. [Methemoglobin synthesis during azulfidine therapy].
    Miller B; Engelhart A; Goebel KM; Schmidt J; Martini GA
    Verh Dtsch Ges Inn Med; 1971; 77():1326-30. PubMed ID: 4405361
    [No Abstract]   [Full Text] [Related]  

  • 28. [Side effects of azulfidine therapy].
    Miller B
    Med Welt; 1976 Jul; 27(27):1334-5. PubMed ID: 8688
    [No Abstract]   [Full Text] [Related]  

  • 29. Salicylazosulfapyridine in clinical practice.
    Goldman P; Peppercorn MA
    Gastroenterology; 1973 Jul; 65(1):166-9. PubMed ID: 4146457
    [No Abstract]   [Full Text] [Related]  

  • 30. Reversible toxic effect of salicylazosulfapyridine on semen quality.
    Toth A
    Fertil Steril; 1979 May; 31(5):538-40. PubMed ID: 36307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum sickness with pseudolymphomatous lymph node hyperplasia caused by salicylazosulfapyridine].
    Delage C; Lagacé R
    Union Med Can; 1975 Apr; 104(4):579-84. PubMed ID: 4911
    [No Abstract]   [Full Text] [Related]  

  • 32. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis.
    Walker AM; Szneke P; Bianchi LA; Field LG; Sutherland LR; Dreyer NA
    Am J Gastroenterol; 1997 May; 92(5):816-20. PubMed ID: 9149192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azulfidine agranulocytosis with bone marrow, megakaryocytosis, histiocytosis and plasmacytosis.
    Jamshidi K; Arlander T; Garcia MC; Windschitl HW; Swaim WR
    Minn Med; 1972 Jun; 55(6):545-8. PubMed ID: 4402375
    [No Abstract]   [Full Text] [Related]  

  • 34. [Agranulocytosis during treatment with salicylazosulfapyridine (Salazopyrin)].
    Marstein S
    Tidsskr Nor Laegeforen; 1969 Oct; 89(19):1484-7. PubMed ID: 4392789
    [No Abstract]   [Full Text] [Related]  

  • 35. Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.
    Pounder RE; Craven ER; Henthorn JS; Bannatyne JM
    Gut; 1975 Mar; 16(3):181-5. PubMed ID: 235486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).
    Dissanayake AS; Truelove SC
    Gut; 1973 Dec; 14(12):923-6. PubMed ID: 4150435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term immunosuppressive therapy of ulcerative colitis. Continuation of a personal series.
    Korelitz BI; Glass JL; Wisch N
    Am J Dig Dis; 1973 Apr; 18(4):317-22. PubMed ID: 4144440
    [No Abstract]   [Full Text] [Related]  

  • 38. Desensitization for sulfasalazine-induced skin rash in a patient with ulcerative colitis.
    Akahoshi K; Chijiiwa Y; Kabemura T; Okabe H; Akamine Y; Nawata H
    J Gastroenterol; 1994 Dec; 29(6):772-5. PubMed ID: 7874275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute ulcerative colitis--a rare complication of sulfasalazine therapy.
    Ruppin H; Domschke S
    Hepatogastroenterology; 1984 Aug; 31(4):192-3. PubMed ID: 6148297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.